Skip to main content
. Author manuscript; available in PMC: 2009 Jul 15.
Published in final edited form as: Cancer Res. 2008 Jul 15;68(14):5839–5848. doi: 10.1158/0008-5472.CAN-07-5771

Figure 3.

Figure 3

Ovarian cancer cell proliferation response to PAF treatment is PAFR-dependent. A. Normal HOSE cells (without PAFR expression) showed no response with different concentrations of PAF treatment. Treatment of PAF with ginkgolide B showed no-response in HOSE cell proliferation. B. Mucinous type ovarian cancer cells RMUG-L (negative PAFR expression) showed no response to PAF treatment in cell proliferation and a little effect on cell proliferation when treated together with 100 μM ginkgolide B. C-D. Ovarian cancer cell lines OVCA429 and OVCA432 showed a strong and dose-dependent response to PAF treatment and significantly increases in cell proliferation. Both PAFR antagonist, ginkgolide B ( ) and specific antibody against PAFR (▲) have significantly blocked the PAF-induced cell proliferation, compared with treatment of PAF alone (◆) or PAF with IgG control (Δ) (p<0.001).